T2以下の局在性前立腺癌における治療成績をretrospectiveに検討した.conventionalな外照射療法の根治性は前立腺全摘除術に比較して低く, 放射線療法の適応としては, 期待余命の限られた局在性前立腺癌に限定されるものと思われた.前立腺癌へのradiosurgeryの応用は可能と考えられたFifty-seven patients with clinically localized prostate cancer were treated by radical prostatectomy or external radiation therapy following pelvic lymphadenectomy. Comparing the outcome of radiotherapy with that of prostatectomy in 42 T2 patients without lymph node metastasis, the 5-year cause-specific survival did not differ between the radical prostatectomy group (n = 31) and radiotherapy group (n = 11). The 5-year disease-free survival of the prostatectomy group, however, was superior to that of radiotherapy group (p = 0.01). To cure patients with T2 prostate cancer, therefore, it is su...
Prostate cancer (PC) is one of the most prevalent cancers in men and the second leading cause of can...
The results of treatment of 170 patients with prostate cancer (T2—3N0—1M0—1) who received radiothera...
For a patient suffering from non-metastatic prostate cancer, the individualized recommendation of ra...
リンパ節転移陰性例の5年非再発率は, 手術群94%, 放射線群41%で, 手術群の成績が有意に良好であった.根治を目的とした場合, リンパ節転移陰性例では手術療法を第一選択とすべきと考えられたBetw...
放射治疗目前不仅用于早期局限性前列腺癌的根治性治疗,亦逐渐应用于局部晚期前列腺癌的治疗、手术后的辅助性治疗以及与内分泌联合治疗.除外照射放射治疗外,组织间插植放射治疗,3-D适形放射治疗等技术也愈来愈...
20世纪50年代用外照射的方法广泛治疗前列腺癌,尽管放疗技术有某些改进,但常规放射治疗的剂量只是65Gy~70Gy.常规外射线治疗最大程度也只能控制局限的前列腺癌.最近研究用三维适形放射治疗(3-DC...
Prostate cancer is one of the most common malignancies in men. Radiotherapy is one of the main treat...
Prostate cancer is the second most common cancer in men and a major cause of cancer deaths worldwide...
Prostate cancer is a heterogeneous, indolent or sometimes aggressive tumor. Treatment options are va...
Radiotherapy (RT) for prostate cancer (PC) has steadily evolved over the last decades, with improvin...
International audiencecIntensity-modulated radiation therapy, image-guided radiation therapy with fi...
前列腺癌(prostate cancer,PCa)放射性粒子近距离治疗近年在国外发展迅速,因其方法简便、疗效显著,已成为治疗早期PCa的一种行之有效的选择.04554-5580
The standard treatment options based on the risk category (stage, Gleason score, PSA) for localized ...
Prostate cancer is a heterogeneous, indolent or sometimes aggressive tumor. Treatment options are va...
Purpose of our study is to carry out: comparative analysis of results of radical prostatectomy and c...
Prostate cancer (PC) is one of the most prevalent cancers in men and the second leading cause of can...
The results of treatment of 170 patients with prostate cancer (T2—3N0—1M0—1) who received radiothera...
For a patient suffering from non-metastatic prostate cancer, the individualized recommendation of ra...
リンパ節転移陰性例の5年非再発率は, 手術群94%, 放射線群41%で, 手術群の成績が有意に良好であった.根治を目的とした場合, リンパ節転移陰性例では手術療法を第一選択とすべきと考えられたBetw...
放射治疗目前不仅用于早期局限性前列腺癌的根治性治疗,亦逐渐应用于局部晚期前列腺癌的治疗、手术后的辅助性治疗以及与内分泌联合治疗.除外照射放射治疗外,组织间插植放射治疗,3-D适形放射治疗等技术也愈来愈...
20世纪50年代用外照射的方法广泛治疗前列腺癌,尽管放疗技术有某些改进,但常规放射治疗的剂量只是65Gy~70Gy.常规外射线治疗最大程度也只能控制局限的前列腺癌.最近研究用三维适形放射治疗(3-DC...
Prostate cancer is one of the most common malignancies in men. Radiotherapy is one of the main treat...
Prostate cancer is the second most common cancer in men and a major cause of cancer deaths worldwide...
Prostate cancer is a heterogeneous, indolent or sometimes aggressive tumor. Treatment options are va...
Radiotherapy (RT) for prostate cancer (PC) has steadily evolved over the last decades, with improvin...
International audiencecIntensity-modulated radiation therapy, image-guided radiation therapy with fi...
前列腺癌(prostate cancer,PCa)放射性粒子近距离治疗近年在国外发展迅速,因其方法简便、疗效显著,已成为治疗早期PCa的一种行之有效的选择.04554-5580
The standard treatment options based on the risk category (stage, Gleason score, PSA) for localized ...
Prostate cancer is a heterogeneous, indolent or sometimes aggressive tumor. Treatment options are va...
Purpose of our study is to carry out: comparative analysis of results of radical prostatectomy and c...
Prostate cancer (PC) is one of the most prevalent cancers in men and the second leading cause of can...
The results of treatment of 170 patients with prostate cancer (T2—3N0—1M0—1) who received radiothera...
For a patient suffering from non-metastatic prostate cancer, the individualized recommendation of ra...